REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered And Includes At Least Nitrogen And Oxygen As Ring Hetero Atoms (e.g., Monocyclic 1,2- And 1,3-oxazines, Etc.) > Morpholines (i.e., Fully Hydrogenated 1,4- Oxazines) > Chalcogen Attached Indirectly To The Morpholine Ring By Acyclic Nonionic Bonding Chalcogen Attached Indirectly To The Morpholine Ring By Acyclic Nonionic BondingChalcogen Attached Indirectly To The Morpholine Ring By Acyclic Nonionic Bonding patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010517 - Pharmaceutical salts of reboxetine The present invention relates to novel crystalline, water-soluble salts of the 2S,3S enantiomer of reboxetine, which are the fumarate and succinate salts thereof, to a process for their preparation, to their utility in therapy and to pharmaceutical corn-positions containing them. ... 11/23/06 - 20060264436 - Method of treating a psychotic disorder Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about ... 06/29/06 - 20060142290 - Compositions for affecting weight loss Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are ... 06/29/06 - 20060142289 - Method of treating migraine headaches Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about ... 06/29/06 - 20060142288 - Combinations and methods for headaches The present invention provides pharmaceutical agents for preventing headaches, especially headaches associated with migraine, tension headaches, and chronic daily headaches. The prophylactic treatments in accordance with the present invention can reduce the frequency of headaches, such as migraine attacks, as well as reducing their severity and duration when they do ... 06/29/06 - 20060142287 - Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer An improved adjuvant treatment of stage I or II breast cancer in which patients are administered a chemotherapeutic agent active in breast cancer is provided in which a diphenyl compound which is a potent antagonist of histamine binding at the intracellular histamine receptor is initially administered prior to administration of ... 06/22/06 - 20060135521 - Method of treating chronic fatigue syndrome Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about ... 06/22/06 - 20060135520 - Method of treating peripheral neuropathy Methods and compositions for treating humans suffering from or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about ... 03/16/06 - 20060058300 - Intermediates of bupropion metabolites synthesis Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed. ... 03/09/06 - 20060052377 - Benzyl morpholine derivatives A compound of formula (I) (I) wherein R is H; Ar is an aromatic group selected from phenyl; X is a phenyl group; R′ H or C1-C4 alkyl; each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof. ... 09/29/05 - 20050215552 - Method for treating obesity The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition ... ### FreshPatents.com Support |